Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957026 | 1.00 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL9945925 | 0.88 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3790902 | 0.87 | ALDH1A1 (0.47) | L3MBTL1ALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3316374 | 0.86 | L3MBTL1 (0.44) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL29952625 | 0.86 | L3MBTL1 (0.44) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL29954630 | 0.85 | L3MBTL1 (0.46) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL12538526 | 0.85 | L3MBTL1 (0.46) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL28580785 | 0.83 | PTPN1 (0.41) | L3MBTL1ALDH1A1TDP1 | |
| SCHEMBL29952804 | 0.81 | L3MBTL1 (0.33) | L3MBTL1ALDH1A1TDP1 | |
| SCHEMBL519872 | 0.79 | ENPP2 (0.50) | L3MBTL1ALDH1A1TDP1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| US-12466815-B2 | Carboxamide compounds and uses thereof | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | ENANTA PHARM INC (US) | 2024-08-08 | — | — | US | disclosed |
| US-20240150326-A1 | CARBOXAMIDE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-05-09 | — | — | US | disclosed |
| CN-112292380-B | N- (phenyl) -2- (phenyl) pyrimidine-4-carboxamide derivatives and related compounds as HPK1 inhibitors for the treatment of cancer | 因赛特公司 | 2024-04-05 | — | — | CN | disclosed |
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2024-02-08 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| EP-2391619-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | disclosed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | L3MBTL1 4173/4885ALDH1A1 2205/4885CYP1A2 1509/4885 |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | L3MBTL1 4393/4885ALDH1A1 4010/4885CYP1A2 2891/4885 |
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | HCCS, HAVCR2, HDGF | L3MBTL1 4720/4885ALDH1A1 2352/4885CYP1A2 222/4885 |
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | L3MBTL1 1899/4885ALDH1A1 1355/4885CYP1A2 3102/4885 |
| US-20240150326-A1 | CARBOXAMIDE COMPOUNDS AND USES THEREOF | PCK1, PHKG2, PHKG1 | L3MBTL1 3347/4885ALDH1A1 2561/4885CYP1A2 2080/4885 |
| US-20110003807-A1 | Thiazole derivatives | MTOR, RICTOR, AKT2 | L3MBTL1 2095/4885ALDH1A1 1687/4885CYP1A2 1643/4885 |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | L3MBTL1 1874/4885ALDH1A1 1749/4885CYP1A2 2482/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | L3MBTL1 1465/4885ALDH1A1 728/4885CYP1A2 224/4885 |
| US-12466815-B2 | Carboxamide compounds and uses thereof | PCK1, PHKG2, PHKG1 | L3MBTL1 3347/4885ALDH1A1 2561/4885CYP1A2 2080/4885 |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | L3MBTL1 4173/4885ALDH1A1 2205/4885CYP1A2 1509/4885 |
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | L3MBTL1 4720/4885ALDH1A1 2352/4885CYP1A2 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.